Item 2.02. Results of Operations and Financial Condition.
On August 3, 2021, Neurocrine Biosciences, Inc. announced its financial results
for the second quarter ended June 30, 2021. The full text of the press release
issued in connection with the announcement is attached as Exhibit 99.1 to this
Current Report on Form 8-K.
In accordance with General Instruction B.2 of Form 8-K, the information in this
Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed"
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the "Exchange Act") or otherwise subject to the liability of that section, nor
shall it be deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended, or the Exchange Act, except as expressly set forth by
specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
Exhibit        Description

       99.1      Press Release dated August 3, 2021

        104    Cover Page Interactive Data File


--------------------------------------------------------------------------------

© Edgar Online, source Glimpses